Correction to “RTP801 is a critical factor in the neurodegeneration process of A53T a-synuclein in a mouse model of Parkinson's disease under chronic restraint stress”

IF 6.8 2区医学 Q1 PHARMACOLOGY & PHARMACY

British Journal of Pharmacology Pub Date : 2024-08-29 DOI:10.1111/bph.17323

引用次数: 0

Abstract

Zhang, Z, Chu, SF, Wang, SS, Jiang, YN, Gao, Y, Yang, PF, Ai, QD, Chen, NH. RTP801 is a critical factor in the neurodegeneration process of A53T α-synuclein in a mouse model of Parkinson's disease under chronic restraint stress. Br J Pharmacol. 2018 Feb; 175(4): 590–605, https://doi.org/10.1111/bph.14091

Accidental mistakes during article preparation led to wrong in Figure 8e. The images of A53T+RTP801 shRNA+CRS group in Figure 8e were incorrect. The corrected figure is provided below. All other data in Figure 8e remain unchanged, and this correction does not affect the interpretation of the results or the conclusions of the paper.

We apologise for this error.

查看原文本刊更多论文

更正："RTP801是帕金森病小鼠模型中A53T a-突触核蛋白在慢性束缚应激下神经变性过程中的关键因素"。

Zhang, Z, Chu, SF, Wang, SS, Jiang, YN, Gao, Y, Yang, PF, Ai, QD, Chen, NH. RTP801是帕金森病小鼠模型在慢性束缚应激下A53T α-突触核蛋白神经变性过程中的关键因子Br J Pharmacol. 2018 Feb; 175(4)：590-605, https://doi.org/10.1111/bph.14091Accidental 文章编写过程中的错误导致图 8e 中的错误。图 8e 中 A53T+RTP801 shRNA+CRS 组的图像有误。更正后的图如下。图 8e 中的所有其他数据保持不变，此次更正不影响对结果的解释或论文的结论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Pharmacology 医学-药学

CiteScore

15.40

自引率

12.30%

发文量

270

审稿时长

2.0 months

期刊介绍： The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries. Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues. In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.